TWISTlung
EMT, Reactivation of Embryonic Transcription Factors and Alteration of the miR Signaling Network as Pronostic and Predictive Markers in Lung Cancer
Sponsor study identifier
observational
1,000
1 country
1
Study Start
October 20, 2014
Actual (reported)Primary Completion
March 31, 2018
Actual (reported)Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC. This study will potentially lead to specific treatment recommendations, thanks to an integrated molecular approach including DNA, RNA and miR profiling In vitro analyses using lung cancer cell lines will subsequently be conducted to validate markers identified in tumor screenings.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 20, 2014
Actual (reported)March 31, 2018
Actual (reported)April 17, 2018
Actual (reported)April 26, 2018
Actual (reported)December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Relapse free survival
Time to relapse after surgery
1 year
Overall survival
Time to death
5 years
Overall survival
3 years
NSCLC localized disease treated by surgery
All patients treated by surgery at HEGP having signed the ONCOHEGP consent are eligible to this observational study
Aphp Hegp
Paris, 75015, France
Garinet S, Didelot A, Marisa L, Beinse G, Sroussi M, Le Pimpec-Barthes F, Fabre E, Gibault L, Laurent-Puig P, Mouillet-Richard S, Legras A, Blons H. A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma. J Transl Med. 2023 May 15;21(1):324. doi: 10.1186/s12967-023-04086-7.
Tumor samples analyzed for somatic mutations using NGS
Francoise Lepimpec Barthes, MD PhD
APHP
First Submitted
April 17, 2018
First Posted
April 26, 2018
Study Start
October 20, 2014
Actual (reported)Primary Completion
March 31, 2018
Actual (reported)Optimizing the Care Pathways of Patients Treated for Operable Breast.
Contact the study team to confirm eligibility.
Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
September 6, 2018
Record last verified: 2018-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: